October 13th 2024
Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
September 30th 2024
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Olaparib Reduced Pain and Yielded Better-Preserved HRQOL in Metastatic CRPC
May 19th 2022Results from a phase 3 trial indicated that olaparib yielded better-preserved health-related quality of life and reduced pain burden vs the control for patients with homologous recombination repair gene–altered metastatic castration-resistant prostate cancer who progressed following a prior next-generation hormonal drug.
Genetically-Adjusted PSA May Be a More Accurate vs PSA Alone as Prostate Cancer Screening Biomarker
April 11th 2022Genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.
18F-Fluciclovine Vs 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence
April 3rd 2022Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the manuscript titled, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler and colleagues.
FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer
March 23rd 2022Based on data from the phase 3 VISION trial, 177Lu-PSMA-617 may now be used to treat patients who were previously treated with androgen receptor pathway inhibitors plus taxane-based chemotherapy for metastatic prostate specific membrane antigen–positive castration-resistant prostate cancer.
Merseburger Discusses Future Research of PRESIDE Trial Enzalutamide Combo
March 23rd 2022Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.